Direkt zum Inhalt
Merck

T-039

Supelco

Topiramate solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

1 ML
CHF 132.00

CHF 132.00


Check Cart for Availability

Bulk-Bestellung anfordern

Größe auswählen

Ansicht ändern
1 ML
CHF 132.00

About This Item

Empirische Formel (Hill-System):
C12H21NO8S
CAS-Nummer:
Molekulargewicht:
339.36
EG-Nummer:
UNSPSC-Code:
41116107
NACRES:
NA.24

CHF 132.00


Check Cart for Availability

Bulk-Bestellung anfordern

Qualität

certified reference material

Form

liquid

Leistungsmerkmale

Snap-N-Spike®/Snap-N-Shoot®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

Konzentration

1.0 mg/mL in methanol

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

clinical testing

Format

single component solution

Lagertemp.

−20°C

SMILES String

CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1

InChI

1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1

InChIKey

KJADKKWYZYXHBB-XBWDGYHZSA-N

Allgemeine Beschreibung

A certified solution standard suitable for use in LC/MS or GC/MS applications for pharmaceutical research, clinical toxicology, or forensic testing.  Topiramate, sold under trade name Topamax®, is an antiepileptic drug used for treatment of seizures. Topiramate in combination with the stimulant phentermine constitute the active compounds in the new weight lose drug Qsymia®.

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Qsymia is a registered trademark of Vivus, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Topamax is a registered trademark of Johnson & Johnson

Ähnliches Produkt

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Zielorgane

Eyes

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 1

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 3

1 of 3

J M Riffitts et al.
Journal of pharmaceutical and biomedical analysis, 19(3-4), 363-371 (2000-03-07)
An accurate and robust method involving liquid liquid extraction and capillary gas chromatographic (GC) assay with nitrogen phosphorus detection (NPD) was developed and validated for the quantitative determination of topiramate [2,3:4,5-bis-O-(-1-methylethylidene)-beta-D-fructopyranose sulfamate], Topamax, an anticonvulsant drug, in human plasma, urine
Annie M Clark et al.
Epilepsia, 55(7), 1069-1076 (2014-05-28)
Evaluate the pharmacokinetics (PK), safety, and tolerability of single doses of once-daily USL255, Qudexy XR (topiramate) extended-release capsules, over a wide dosing range. Two single-dose, phase I studies in healthy adults were used to evaluate the PK profile and maximum
Steve S Chung et al.
Epilepsia, 55(7), 1077-1087 (2014-06-07)
To evaluate the efficacy and safety of USL255, Qudexy(™) XR (topiramate) extended-release capsules, as an adjunctive treatment for refractory partial-onset seizures (POS) in adults taking one to three concomitant antiepileptic drugs. In this global phase III study (PREVAIL; NCT01142193), 249
William Timothy Garvey
Expert opinion on drug safety, 12(5), 741-756 (2013-06-07)
Weight-management options include lifestyle modifications, bariatric surgery and, until recently, limited pharmacotherapy. Phentermine and topiramate extended-release (phentermine/topiramate ER) has recently been approved in the USA for chronic weight management in obese adults and overweight adults with weight-related co-morbidities in conjunction
Elizabeth M Kelly et al.
Journal of managed care pharmacy : JMCP, 19(8), 642-654 (2013-10-01)
Obesity may lead to the development of multiple chronic disease states, including hypertension, dyslipidemia, and type 2 diabetes mellitus. Over a half billion adults worldwide are affected by obesity, and more than two-thirds of adults are either obese or overweight

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.